It’s always a good idea to pay attention to 13F filings.

Or, the reports filed by institutions within 45 days of the end of a quarter. These filings, required from firms with more than $100 million in assets under management, disclose new holdings and sales of publicly traded stocks, options and warrants.

In the most recent 13F filings, we learned that billionaire Stanley Druckenmiller, the billionaire behind the Duquesne Family Office, bought more than 7.5 million shares of Teva Pharmaceuticals (TEVA).

Start pulling in more than a part time job. In about 5-10 min a day you can make more than most sidehustles. Click here to check it out for just $1.

Teva Pharmaceuticals (TEVA)

At the end of 2024, he acquired 7,569,450 shares of TEVA, which increased the firm’s stake by 530% and made TEVA Duquesne’s fourth biggest holding.

Granted, TEVA was a bad stock to hold for a while.

Between July 2015 to April 2025, the stock slipped from $65.81 to less than $8 a share. But that’ll happen when you get caught up in litigation over the opioid crisis. It also lost its sales exclusivity with its multiple sclerosis drug and had considerable debt on the books.

However, shares of TEVA are starting to come back strong.

It’s also been able to put the opioid litigation in its rearview mirror, which was settled with 48 states for about $4.25 billion in 2022. That’s payable over 13 years so it won’t drain its cash.

TEVA is also inexpensive, trading at 5.24x earnings with a PEG ratio of just 0.82. 

Sincerely,

Ian Cooper